Researchers reviewed existing studies on a protein called neutrophil gelatinase-associated lipocalin (NGAL). They wanted to see if measuring NGAL levels could help doctors manage two serious kidney-related problems: sudden kidney injury (acute kidney injury or AKI) and a dangerous infection called peritoneal dialysis-related peritonitis (PDRP) in people on a specific type of dialysis.
The review found that NGAL has shown significant promise as a tool for the early detection and diagnosis of acute kidney injury. For patients with peritoneal dialysis-related peritonitis, the review suggests NGAL may also be useful for identifying the infection and for monitoring how well a patient responds to treatment. However, the review noted that evidence for using NGAL in people with long-term kidney disease or kidney transplants is still relatively limited.
It is important to understand that this was a narrative review, which summarizes and discusses past research but does not provide new data or a strict statistical analysis of all evidence. The review did not report on the size of the studies, the specific patient groups involved, or any safety concerns. Because this is not a new clinical trial, the findings represent a hopeful direction for future research, not a current standard of care. Doctors and patients should wait for more definitive studies before considering NGAL a routine tool for managing these conditions.
